Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ANTIGEN-SPECIFIC ANTIBODY-RESPONSES IN LUPUS PATIENTS FOLLOWING IMMUNIZATION
Autore:
BATTAFARANO DF; BATTAFARANO NJ; LARSEN L; DYER PD; OLDER SA; MUEHLBAUER S; HOYT A; LIMA J; GOODMAN D; LIEBERMAN M; ENZENAUER RJ;
Indirizzi:
ACAD HLTH SCI,DEPT MED SCI,MCCS-HM,STE 1230,3151 SCOTT RD FT SAM HOUSTON TX 78234 FITZSIMONS ARMY MED CTR AURORA CO 80045 BROOKE ARMY MED CTR FT SAM HOUSTON TX 78234
Titolo Testata:
Arthritis and rheumatism
fascicolo: 10, volume: 41, anno: 1998,
pagine: 1828 - 1834
SICI:
0004-3591(1998)41:10<1828:AAILPF>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
PNEUMOCOCCAL POLYSACCHARIDE VACCINE; INFLUENZA VACCINATION; PROTECTIVE EFFICACY; HIGH-RISK; ERYTHEMATOSUS; TETANUS; DIPHTHERIA; CRITERIA; TOXOIDS; TRIAL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
46
Recensione:
Indirizzi per estratti:
Citazione:
D.F. Battafarano et al., "ANTIGEN-SPECIFIC ANTIBODY-RESPONSES IN LUPUS PATIENTS FOLLOWING IMMUNIZATION", Arthritis and rheumatism, 41(10), 1998, pp. 1828-1834

Abstract

Objective. To determine the safety and efficacy of 3 clinically relevant vaccines in patients with systemic lupus erythematosus (SLE). Methods. We studied 73 consecutive SLE patients immunized with pneumococcal, tetanus toroid (TT), and Haemophilus influenzae type B (HIB) vaccines. Patients were evaluated preimmunization and 12 weeks postimmunization for disease activity and immunization side effects. Results. Eighty-four percent of the SLE patients developed a 4-fold titer increase in response to at least 1 vaccine with 51% developing a 2-fold titer increase with all 3 vaccines. The majority of SLE patients developed protective levels of antibody to TI (90%) and HIB (88%). Although protective antibody levels could not be determined for pneumococcus, almost half of the patients (47%) developed a 4-fold antibody response. There was a trend toward a lower antibody response in patients with active disease treated with immunosuppressive therapy. Overall lupus disease activity was unaffected by immunization. Conclusion. Immunization is safe in SLE patients,,vith the overwhelming majority developing protective antibody levels. Therefore, SLE patients should receive immunizations according to the recommendations of the Centers for Disease Controland Prevention and the Immunization Practices Advisory Committee.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/12/20 alle ore 21:11:32